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Background: Although myeloperoxidase (MPO)  and
adenosine-deaminase  (ADA)  levels  are  markers  of
activated  leukocytes,  both  enzymes  have  not  been
currently addressed in inflammation models.
Aims:  This  study  evaluates  whether  the  concentra-
tions  of  these  enzymes  are  significantly  correlated
with the content of leukocytes in a pleurisy model.
Methods: The pleurisy  was induced by carrageenan
(1%) in mice, and the parameters analyzed 4 and 48h
after.
Results:  After  the  induction  of  inflammation  (4h),
MPO and ADA levels peaked in parallel to neutrophils
(p <  0.01).  Regarding the  second  phase  of pleurisy
(48h), the highest concentrations of ADA were detec-
ted in parallel to the highest levels of mononuclears
(p < 0.01). At this time, MPO levels and neutrophils
remained  elevated,  although  at  lower  levels  than
those found at 4h. A significant positive correlation
was found among neutrophils and MPO, and mono-
nuclears and ADA (p < 0.01).
Conclusions:  These  findings  support  the  evidence
that both enzymes are markers of the inflammatory
process,  and provide  new tools  for  a  better  under-
standing  of  the  immunoregulatory  pathways  that
occur in inflammation.
Key  words:  Adenosine-deaminase,  Myeloperoxidase,
Mouse pleurisy, Inflammation
Introduction
Many studies have demonstrated that the release of
myeloperoxidase  (MPO)  or  adenosine  deaminase
(ADA) from leukocytes at the site of injury reflects the
activation  of  both  neutrophils  and  lymphocytes.1,2
Myeloperoxidase is a leukocyte component able to
generate  potent  microbicidal  products  and  it  is
recognized that it facilitates cell adhesion, mainly via
CD11b/CD18, a function that may be of considerable
importance  for  leukocyte  migration.3,4 In  addition,
ADA activity originates from the action of isoenzymes
ADA-1  and ADA-2.  Increased ADA activity  has been
found in the pleural fluid and serum of tuberculous
patients as well as in the serum of patients suffering
from  leprosy,  cutaneous  leishmaniosis,  brucellosis,
salmonellosis and human deficiency virus infection. It
has also been found in subjects with renal allograft
transplants undergoing acute graft rejection.1,5–10 On
the  contrary,  based  on  these  findings,  these  two
markers  constitute  valuable  tools  for  use  in  the
evaluation of the degree of inflammation.1,4
Since  very  little  data  is  available  regarding  the
changes  in  the  two  enzymes  during  acute  and/or
chronic inflammation, the aim of the present study was
to  examine  whether  the  concentrations  of  both
enzymes are significantly  correlated with the differ-
ential contents of leukocyte cells, namely neutrophils
and  lymphocytes,  in  a  pleurisy  model  induced  by
carrageenan (1%) in mice. A major characteristic of this
model is the biphasic profile of cell migration charac-
terized by an early (4h) and late (48h) cell migration of
neutrophils  and  mononuclear  cells,  respectively.11
These two phases of  the  inflammatory  response  to
carrageenan in  the mouse pleural  cavity are named
‘first’ (or ‘early’) and ‘second’ (or ‘late’) phases.
Methods
Animals
Non-fasted adult Swiss mice of both sexes (18–25g),
aged  2  months,  were  used  throughout  the  experi-
ments. The animals were kept in an environmentally
controlled room, temperature 21 ± 2°C, under a light/
dark cycle of 12h, and were allowed free access to
food  and  water.  Animals  were  managed  using  the
principles and guidelines for the care of laboratory
animals according to Zimmermann.12
Experimental design
Induction and analysis of pleurisy
As previously reported,11,13 the mouse pleurisy was
induced by a single intrapleural injection of 0.1ml of
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caused by carrageenan exhibits a biphasic response (4
and  48h),  both  interval  points  were  chosen  to
determine the levels of both MPO and ADA.
After killing the animals with an overdose of ether,
the  thorax was opened and the  pleural  cavity was
washed  with  1.0ml  of  sterile  phosphate-buffered
saline  (PBS)  containing  heparin  (20IU/ml).  Several
samples  of  the  pleural  lavage  were  collected  for
further determination of both MPO and ADA activities
as well  as total and differential  leukocyte contents.
Total leukocyte counts were performed on an auto-
matic counting machine (Beckman Coulter, Inc., Brea,
CA, USA), whereas cytospin preparations of pleural
washing were stained with May-Grunwald-Giemsa for
the  differential  count  of  leukocytes,  which  was
performed under an immersion objective.
Enzymatic assays
In-house assays of both MPO and ADA were employed
according to the methods developed by Rao et al.14
and  Giusti  and  Galanti.14,15 Using  conventional
reagents,  each  enzymatic  concentration  was  esti-
mated  by  means  of  colorimetric  measurements
(absorbances of  450  and 630nm,  respectively) in a
Hitachi  spectrophotometer  (U-2001,  San  Jose,  CA,
USA). One unit of MPO is defined as the activity of the
enzyme that oxides 1mol of H2O2/min, whereas one
unit of ADA is equivalent to the amount of enzyme
required to release 1mmol of ammonia/min. Results
were expressed as mU/ml (MPO) and U/l (ADA).
Myeloperoxidase assay
Standard  samples  with  different  concentrations  of
myeloperoxidase (from  human  neutrophils, M6908,
St.  Louis,  MO,  USA)  were  prepared  to  obtain  a
standard  curve  in  the  range  of  0.07–140mU/ml.
Pleural aliquots (40m l) and standards were transferred
to cuvettes and the reaction was initiated with the
addition  of  360 m l  of  assay  buffer  (0.167mg/ml  of
o-dianisidine 2HCl and 0.0005% H2O2). The reaction
was stopped with sodium azide 1%. Afterwards, the
samples  were  centrifuged  at  50 ´ g for  5min,  the
supernatants were separated, and the rates of changes
in  absorbancy  were  determined.  MPO  activity  was
estimated by  interpolation from the standard curve
already  described.  Samples  in  which  the  levels  of
MPO  were  above  the  higher  limit  of  detection
(140mU/ml) were diluted (two- to fivefold) and the
concentrations  were  corrected  for  the  twofold  to
fivefold  dilution,  whereas  results  below  the  lower
limit of detection were expressed as 0.7mU/ml.
Adenosine-deaminase assay
Initially, standard samples (final volume of 500 m l) with
different  volume  concentrations  of  NaH2PO4·H2O
(35 mM),  Na2HPO4·H2O  (15 mM)  and  of  NH3SO4
(15 mM) were prepared to obtain a standard curve in
the range of 10–50U/l. Pleural fluid samples (20 m l)
were  transferred  to  cuvettes  and  the  reaction  was
initiated  by  the  addition  of  adenosine  phosphate-
buffered solution (pH 6.5, 500 m l; composition, NaH2-
PO4·H2O  (35 mM),  Na2HPO4·12H2O  (15 mM)  and
adenosine (0.5 mM)). After incubation for 1h at 37°C,
the reaction was halted with the addition of a solution
(1000 m l)  of  phenol  (1 mM)  and  nitroprussiate
(0.17 mM),  plus  alkaline  buffer  (1000 m l:  NaOCl,
11 mM). This solution (final volume of 2000 m l) was
also added to the cuvettes with the different standard
samples. Afterwards, the rate of change in absorbancy
was  determined.  ADA  activity  was  estimated  by
interpolation from the standard curve already descri-
bed. The reagents were stable at 2–8°C for 1 month.
Drugs
Carrageenan (degree IV), dianisidine 2HCl (3,39 -dime-
thoxybenzidine), sodium azide, human polymorpho-
nuclear leukocyte myeloperoxidase (Sigma, St, Louis,
MO, USA), NaH2PO4·H2O, Na2HPO4·12H2O, NH3SO4,
nitroprussiate  (Montedison,  S˜ ao  Paulo,  SP,  Brazil),
adenosine (Sigma, St. Louis, MO, USA), alkaline buffer
(Merck, S˜ ao Paulo, SP,  Brazil), phenol (Biotech, S˜ ao
Paulo, SP, Brazil). NaCl (0.9%), May-Grunwald-Giemsa
dye from different commercial sources. PBS (Merck
(pH  7.6):  composition,  NaCl  (137mmol),  KCl
(2.7mmol) and phosphate buffer salts (10 mM)) was
previously  prepared and maintained in  the refriger-
ator. All drugs were kept in siliconized plastic tubes at
–20°C. On the day of the experiments, the drugs were
diluted to the desired concentration with sterile saline
solution at room temperature.
Statistical analysis
ADA  and  MPO  values  were  analyzed  by  use  of
parametric (analysis of variance and Dunnett) and non-
parametric  (Kruskall-Wallis  and  Dunn)  tests. When
necessary, single linear regression as well as parametric
and non-parametric correlation statistical tests were
also employed. p < 0.05 was considered indicative of
significance. According to the statistical methodology,
values are presented as mean ± 95% confidence limits
(CL) (parametric tests, ADA), mean ± SEM (parametric
tests, total and differential leukocytes) or median plus
range (non-parametric tests, MPO).
Results
In control animals (treated only with buffered-saline
solution), MPO and ADA concentrations were 3.0mU/
ml  (range,  2.0–3.4mU/ml)  and  1.9U/l  (CL,
1.0–2.8U/l), respectively (Fig. 1A,B). Baseline levels
of neutrophil and mononuclear cells (´ 106) were 0.3
± 0.1 and 0.8 ± 0.1 (Fig. 1C,D).
As  shown  in  Fig.  1A,C,  myeloperoxidase  levels
peaked  at  4h  (median,  537.5mU/ml;  range,
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tion in parallel with neutrophils (4.7 ± 0.2 ´ 106).
On  the  contrary,  adenosine-deaminase  levels
peaked both at 4h (mean, 5.6U/l; CL, 5.0–6.2U/l) (p
< 0.01) and 48h (mean, 7.5U/l; CL, 6.8–8.0U/l) (p <
0.01) after pleurisy induction (Fig. 1B). The highest
concentrations  of  ADA  were  detected  at  48h  in
association with highest levels of mononuclears (6.6
± 0.3 ´ 106) (p < 0.01) (Fig. 1B,D). At this time, MPO
levels (median, 158.0mU/ml; range, 146.0–171.0mU/
ml) and neutrophils (1.2 ± 0.2 ´ 106) still remained
elevated, although at lower levels than those found at
4h (Fig. 1A,C). It is interesting to point out that high
levels of ADA were  also detected 4h after pleurisy
induction  in  association  with  neutrophils,  but  not
mononuclear cell migration (Fig. 1).
A  significant  positive  correlation  was  detected
between ADA  levels  and  both  total  leukocyte  (r =
0.73, p < 0.01) and mononuclear cells (r = 0.64, p <
0.01) (Fig. 2A), whereas another positive correlation
MPO and ADA levels in the mouse model of pleurisy
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FIG. 1. Myeloperoxidase (A), adenosine deaminase (B), neutrophil (C) and mononuclear (D) values determined for the pleural
lavage in the early (4h) and late (48h) phases of pleurisy induced by carrageenan in mice. C, Control values obtained for sterile-
saline-treated mice. Symbols indicate the median (MPO) or mean (ADA, neutrophils, mononuclears) values, and the dotted
lines the respective ranges (MPO) or confidence limits (ADA). ** p < 0.01.
FIG. 2. Linear regression analysis among adenoside-deaminase and mononuclears (A), and among myeloperoxidase and
neutrophil (B) levels. Symbols indicate the individual values and the dotted lines the range (MPO) or 95% CL (ADA).was found between neutrophils and MPO (r = 0.47,
P < 0.01) (Fig. 2B).
Discussion
Our  data show  that both MPO and ADA levels  are
increased in the pleurisy reaction induced by carra-
geenan  in  mice.  Considering  that  this  model  of
inflammation  presents  a  biphasic  profile,  charac-
terized by two different pools of leukocyte popula-
tion, these results provide additional information on
the general mechanisms of inflammation.
As a rule, MPO is involved in the killing of several
microorganisms and foreign cells, including bacteria,
fungi,  viruses,  red  cells,  and  malignant  and  non-
malignant  nuclear  cells.3,4 This  enzyme  is  an  iron-
containing heme protein located in  the azurophilic
granules of neutrophil granulocytes and in the lyso-
somes of monocytes.3 Since MPO causes significant
tissue damage, several methods besides that chosen in
our  study  are  available  to  determine  its  content,
including flow cytometry and immunohistochemistry
methods. Its interesting to comment, however, that
the  measurement  of  neutrophil  surface  marker  for
MPO is not a reliable indicator of cell degranulation in
comparison with measurement of the enzyme activ-
ity.2 On  the contrary,  detection of  MPO  inside  the
cells  using  immunohistochemical  techniques  pro-
vides only qualitative  results.2 Our  data is in agree-
ment with that of others’ studies,3,16,17 since it shows
that in this model of inflammation both neutrophils
and MPO peaked in parallel in response to the non-
specific injury caused by carrageenan in the mouse
pleural cavity. Furthermore, the significant fall in MPO
levels in association with a concomitant reduction in
neutrophil level 48h later suggests that the MPO half-
life is very short. In addition, the possibility that MPO
release in the early phase (4h) of the inflammatory
reaction may be related with the events that triggered
the  late mononuclear cell  migration  cannot be dis-
carded. This hypothesis is based on the fact that in
models of  atherosclerosis MPO has  been  shown to
indirectly induce macrophage cell activation.18 Taken
together,  these findings  highlight the evidence that
the employed MPO assay may be used as an indirect
marker  of  neutrophil  activation  in  the  site  of  the
inflammatory process.2
Regarding the role of ADA in inflammation, several
items of data suggest that disturbances in purinergic
signaling mediate the lung inflammation and damage
observed  in  ADA-deficient  mice.19 Recently,  it  has
been demonstrated that this enzyme binds with the
CD26 molecule expressed in some lymphocyte sub-
sets.20 In addition, the possibility that this enzyme can
interact with other cell-surface proteins opens up a
new  perspective for  the  research of  the  immunor-
egulatory mechanisms of the inflammatory process.
In our work, significant levels of ADA were detected
in  both  phases  of  the  model  of  pleurisy  studied.
Although a positive correlation was found between
ADA  and  mononuclear  cell  enhancement  levels,
increased  concentrations  of  this  enzyme  4h  after
pleurisy induction was not clearly associated with an
enhancement  of  mononuclear  cells. These  findings
suggests  that  activation  of  resident  cells  such  as
pleural macrophages may be occurring at this time,
since an increased enhancement of this cell is only
observed 48h after.
In summary, our data provide additional evidence
that both MPO and ADA are involved in this particular
model of pleurisy. Although it is not possible to draw
definitive  conclusions  about  these  results,  these
findings provide new tools for a better understanding
of  the  immunoregulatory  pathway  that  occurs  in
inflammation.
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